上尿路尿路上皮癌外科治疗中国专家共识

2018-11-30 中国抗癌协会泌尿肿瘤专业委员会 现代泌尿外科杂志.2018.23(11):826-829.

上尿路尿路上皮癌(UTUC)并不常见,约占所有尿路上皮癌的5% ~10%,其中肾盂癌约为输尿管癌的2倍。初诊时约有17%患者合并膀胱癌,术后22%~47%患者继发膀胱癌,2%~6%出现对侧上尿路复发。上尿路尿路上皮癌初诊时约60%为浸润性肿瘤,远高于膀胱癌的15%~25%。其高发年龄段在70~90岁,男性发病率为女性3倍。外科治疗是UTUC最主要的治疗方式,包括保肾手术、根治性肾输尿管切除术、淋巴

中文标题:

上尿路尿路上皮癌外科治疗中国专家共识

发布日期:

2018-11-30

简要介绍:

上尿路尿路上皮癌(UTUC)并不常见,约占所有尿路上皮癌的5% ~10%,其中肾盂癌约为输尿管癌的2倍。初诊时约有17%患者合并膀胱癌,术后22%~47%患者继发膀胱癌,2%~6%出现对侧上尿路复发。上尿路尿路上皮癌初诊时约60%为浸润性肿瘤,远高于膀胱癌的15%~25%。其高发年龄段在70~90岁,男性发病率为女性3倍。外科治疗是UTUC最主要的治疗方式,包括保肾手术、根治性肾输尿管切除术、淋巴结清扫术、减瘤性手术、术后辅助治疗和随访。但这些方面学术界还存在不同的意见。 

拓展指南:尿路相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=上尿路尿路上皮癌外科治疗中国专家共识)] GetToolGuiderByIdResponse(projectId=1, id=523021c0016e7599, title=上尿路尿路上皮癌外科治疗中国专家共识, enTitle=, guiderFrom=现代泌尿外科杂志.2018.23(11):826-829., authorId=null, author=, summary=上尿路尿路上皮癌(UTUC)并不常见,约占所有尿路上皮癌的5% ~10%,其中肾盂癌约为输尿管癌的2倍。初诊时约有17%患者合并膀胱癌,术后22%~47%患者继发膀胱癌,2%~6%出现对侧上尿路复发。上尿路尿路上皮癌初诊时约60%为浸润性肿瘤,远高于膀胱癌的15%~25%。其高发年龄段在70~90岁,男性发病率为女性3倍。外科治疗是UTUC最主要的治疗方式,包括保肾手术、根治性肾输尿管切除术、淋巴, cover=, journalId=null, articlesId=null, associationId=1440, associationName=中国抗癌协会泌尿肿瘤专业委员会, associationIntro=, copyright=0, guiderPublishedTime=Fri Nov 30 00:00:00 CST 2018, originalUrl=, linkOutUrl=, content=<div>上尿路尿路上皮癌(UTUC)并不常见,约占所有尿路上皮癌的5% ~10%,其中肾盂癌约为输尿管癌的2倍。初诊时约有17%患者合并膀胱癌,术后22%~47%患者继发膀胱癌,2%~6%出现对侧上尿路复发。上尿路尿路上皮癌初诊时约60%为浸润性肿瘤,远高于膀胱癌的15%~25%。其高发年龄段在70~90岁,男性发病率为女性3倍。外科治疗是UTUC最主要的治疗方式,包括保肾手术、根治性肾输尿管切除术、淋巴结清扫术、减瘤性手术、术后辅助治疗和随访。但这些方面学术界还存在不同的意见。 </div> <div><br> </div> 拓展指南:<strong>与<font color=red>尿路</font>相关指南:</strong><br><ul><li><a href="http://www.medsci.cn/guideline/show_article.do?id=097ae1c00165a93c" title="2018 CUA指南:男性下尿路症状/良性前列腺增生(更新版)" target=_blank>2018 CUA指南:男性下尿路症状/良性前列腺增生(更新版)</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=a60941c00159a8f4" title="2018 AUA指南:良性前列腺增生引起的下尿路症状的手术管理" target=_blank>2018 AUA指南:良性前列腺增生引起的下尿路症状的手术管理</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=7806a1c0015a939d" title="2018 AUGS最佳实践声明:成年女性反复发作性尿路感染" target=_blank>2018 AUGS最佳实践声明:成年女性反复发作性尿路感染</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=2ae491c0015a1123" title="2018 WOCN临床指南:成人粪便或尿路造口的管理" target=_blank>2018 WOCN临床指南:成人粪便或尿路造口的管理</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=4d5d11c001515687" title="中国女性尿路感染诊疗专家共识" target=_blank>中国女性尿路感染诊疗专家共识</a></li> 更多信息请点击:<a href="http://www.medsci.cn/guideline/list.do?q=%E5%B0%BF%E8%B7%AF" target=_blank>有关尿路更多指南</a></ul>, tagList=[TagDto(tagId=84577, tagName=上尿路尿路上皮癌), TagDto(tagId=2738, tagName=外科治疗)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=26, categoryName=泌尿外科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=6803, appHits=192, showAppHits=0, pcHits=5017, showPcHits=3023, likes=134, shares=11, comments=2, approvalStatus=1, publishedTime=Thu Dec 20 22:20:19 CST 2018, publishedTimeString=2018-11-30, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Thu Dec 20 22:20:19 CST 2018, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 11:45:17 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=上尿路尿路上皮癌外科治疗中国专家共识)])
上尿路尿路上皮癌外科治疗中国专家共识
下载请点击:
评论区 (2)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1063453, encodeId=55e1106345342, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4c05646260, createdName=ms9000001361057378, createdTime=Sun Oct 24 15:11:32 CST 2021, time=2021-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355976, encodeId=b6933559e64d, content=学习了很有用不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Fri Dec 21 00:13:29 CST 2018, time=2018-12-21, status=1, ipAttribution=)]
    2021-10-24 ms9000001361057378

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1063453, encodeId=55e1106345342, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4c05646260, createdName=ms9000001361057378, createdTime=Sun Oct 24 15:11:32 CST 2021, time=2021-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355976, encodeId=b6933559e64d, content=学习了很有用不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Fri Dec 21 00:13:29 CST 2018, time=2018-12-21, status=1, ipAttribution=)]
    2018-12-21 飛歌

    学习了很有用不错

    0